Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
CEL-SCI Logo
CEL-SCI Growth Score
86
CB Rank
19832
Heat Score
73
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Founded
obfuscation
PublicPost-IPO Equity Vienna, Virginia, United States11-50 www.cel-sci.com
Biotechnology
Health Care
Medical
Overview

CEL-SCI
Total Funding
obfuscation
Growth Score
86
Heat Score
73

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score86
-3 pts
in past quarter
Heat Score 73
17 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About CEL-SCI

CB Rank
19832
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Founded
obfuscation
PublicPost-IPO Equity Vienna, Virginia, United States11-50 www.cel-sci.com
Biotechnology
Health Care
Medical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name CEL-SCI Corp.
Operating Status Active
Stock Symbol  NYSEMKT:CVM
Company Type For Profit
Founders  Maximilian de Clara
About the Company
CEL-SCI Corporation is a biotechnology company. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.
Phone Number 7035069471
Contact Email Feedback@cel-sci.com
Predictions & Insights

Growth Insight

See this Growth Insight
CEL-SCI is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Multikine
An investigational immunotherapy designed as a first-line neoadjuvant treatment for advanced primary squamous cell carcinoma of the head and neck.
CEL-1000
A peptide-based immunotherapy candidate that acts as a vaccine adjuvant and immune modulator to enhance protection against infectious diseases and cancer in preclinical models.

Research & Development

CEL-SCI is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 18
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 18
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Aegis Capital Corporation Logo
Aegis Capital Corporation
Yes
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
Aegis Capital Corporation Logo
Aegis Capital Corporation
Yes
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
Aegis Capital Corporation Logo
Aegis Capital Corporation
Yes
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
Aegis Capital Corporation Logo
Aegis Capital Corporation
Yes
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
Aegis Capital Corporation Logo
Aegis Capital Corporation
Yes
Post-IPO Equity - CEL-SCI Logo
Post-IPO Equity - CEL-SCI
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 3 Board Members and Advisors 3 Contacts 46

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

423
-26.05%
 in past month

IT Spend

$880.6KThis year, CEL-SCI is projected to spend $880.6K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Workbook Logo
Workbook
100
Purple Team Logo
Purple Team
90
Aspen Ideas Festival Logo
Aspen Ideas Festival
89

Actively Used Products

18CEL-SCI uses 18 technology products and services including HTML5, Lightbox, and  Vimeo, according to G2 Stack.

Active Website Tech Count

8CEL-SCI is actively using 8 technologies for its website, according to BuiltWith. These include Euro, DNSSEC, and  IPv6.

Total IP

12The intellectual property of CEL-SCI includes 11 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, CEL-SCI has 1 registered trademark in the 'Pharmaceutical, veterinary and sanitary products' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is CEL-SCI's headquarters? CEL-SCI is located in Vienna, Virginia, United States.Who invested in CEL-SCI? CEL-SCI has 8 investors including Aegis Capital Corporation and  Rockmore Capital.When was the last funding round for CEL-SCI? CEL-SCI closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are CEL-SCI's competitors? Alternatives and possible competitors to CEL-SCI may include Calidi Biotherapeutics, Canton Strategic Holdings, and  Candel Therapeutics.How much funding has CEL-SCI raised to date? CEL-SCI has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|